REYKJAVIK, Iceland, Feb. 5, 2026 —Alvotech announced positive top-line results from a pivotal pharmacokinetic (PK) study evaluating AVT80, its proposed biosimilar to Entyvio® (vedolizumab). The randomized, double-blind Phase 1 study met all primary endpoints, demonstrating pharmacokinetic similarity, comparable safety, tolerability, and immunogenicity between AVT80 and the reference product in healthy adult participants, marking a key milestone toward global regulatory submissions.
Science Significance
The successful PK study reinforces the scientific foundation of Alvotech’s biosimilar development strategy. AVT80 is a subcutaneous formulation of vedolizumab, a monoclonal antibody targeting the α4β7 integrin, which selectively modulates gut-directed lymphocyte trafficking in inflammatory bowel disease. Demonstrating PK similarity is a cornerstone of biosimilar science, as it confirms comparable exposure, absorption, and elimination profiles between the biosimilar and the reference product. The study’s robust design—randomized, double-blind, and parallel-group—strengthens confidence in AVT80’s clinical comparability and supports the extrapolation of efficacy across indications such as ulcerative colitis and Crohn’s disease.
Regulatory Significance
From a regulatory perspective, the AVT80-GL-P01 study is considered pivotal to support biosimilarity claims for both AVT80 (subcutaneous) and AVT16 (intravenous) formulations. Regulatory agencies require a totality-of-evidence approach, combining analytical similarity, nonclinical data, and clinical PK comparability to establish biosimilarity. Meeting all PK endpoints positions Alvotech to proceed toward regulatory submissions in major markets, including the United States and Europe. The results also reflect adherence to GCP standards, validated clinical operations, and alignment with regulatory guidance for biosimilar monoclonal antibodies.
Business Significance
Advertisement
Commercially, the positive outcome strengthens Alvotech’s competitive position in the rapidly expanding biosimilars market. Entyvio generated approximately US$6.4 billion in global sales in 2025, highlighting the significant market opportunity for high-quality biosimilar alternatives. Advancement of AVT80 and AVT16 expands Alvotech’s immunology portfolio and complements its already approved biosimilars for Humira® and Stelara®. The milestone underscores the company’s fully integrated development and manufacturing model, which combines clinical execution with in-house biologics production to control quality, cost, and scalability.
Patients’ Significance
For patients with inflammatory bowel diseases, biosimilars such as AVT80 offer the potential for improved access and affordability without compromising safety or efficacy. Chronic conditions like ulcerative colitis and Crohn’s disease often require long-term biologic therapy, creating substantial treatment burdens. Successful development of vedolizumab biosimilars may expand therapeutic choice, support healthcare system sustainability, and enable earlier or more consistent access to effective biologic treatments, particularly in regions with cost constraints.
Policy Significance
The advancement of biosimilars aligns with global health policy priorities aimed at enhancing competition, reducing biologic drug costs, and improving patient access. Regulatory agencies worldwide actively encourage biosimilar adoption through clear scientific standards and streamlined approval pathways. Demonstration of PK similarity in rigorously conducted clinical studies supports these policies by ensuring that cost savings do not compromise patient safety or therapeutic outcomes. Biosimilars also play a role in healthcare budget optimization, enabling reinvestment into innovation and advanced therapies.
The positive top-line results from Alvotech’s pivotal PK study represent a significant step forward in the development of AVT80 as a proposed biosimilar to Entyvio®. By meeting all primary endpoints and satisfying critical regulatory expectations, the program advances toward submission readiness while reinforcing the company’s leadership in biosimilar science and manufacturing. As global demand for cost-effective biologics continues to rise, AVT80 and AVT16 may become important additions to the treatment landscape for inflammatory bowel disease.
Source: Alvotech press release
